ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines

References

• Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. ISCOM, A novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature308(5958), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Osterhaus ADME. A novel generation of viral vaccines based on ISCOM matrix. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum, NY, USA 543–558 (1995).
   Google Scholar
• Drane D, Pearse M. The ISCOMATRIX adjuvant. In: Immunopotentiators in Modern Vaccines. Schijns VE, O’Hagan DT (Eds). Elsevier Academic Press, MA, USA 191–216 (2006).
   Google Scholar
• Dalsgaard K. Thin-layer chromatographic fingerprinting of commercially available saponins. Dan. Tidsskr. Farm.44, 327–331 (1970).
   PubMedGoogle Scholar
• Soltysik S, Wu JY, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine13(15), 1403–1410 (1995).
   PubMed Web of Science ®Google Scholar
• Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine13(14), 1375–1382 (1995).
   PubMed Web of Science ®Google Scholar
• Kersten GFA, Crommelin DJA. Liposomes and ISCOMs. Vaccine21(9–10), 915–920 (2003).
   PubMed Web of Science ®Google Scholar
• Waite DC, Jacobson EW, Ennis FA et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine19(28–29), 3957–3967 (2001).
   PubMed Web of Science ®Google Scholar
• Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (ISCOMS). Biotechnol. Appl. Biochem.10(2), 161–172 (1988).
   PubMed Web of Science ®Google Scholar
• Kersten GFA, Spiekstra A, Beuvery EC, Crommelin DJA. On the structure of immune-stimulating saponin-lipid complexes (ISCOMs). Biochim. Biophys. Acta.1062(2), 165–171 (1991).
   PubMed Web of Science ®Google Scholar
• Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T. On the preparation, microscopic investigation and application of ISCOMs. Micron37(8), 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Lenarczyk A, Le TT, Drane D et al. ISCOM based vaccines for cancer immunotherapy. Vaccine22(8), 963–974 (2004).
   PubMed Web of Science ®Google Scholar
• Malliaros J, Quinn C, Arnold FH et al. Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine22(29–30), 3968–3975 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Windon RG, Chaplin PJ, Beezum L et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine19(4– 5), 572–578 (2000).
   PubMed Web of Science ®Google Scholar
• Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol.162(9), 5536–5546 (1999).
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Sjölander S, Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res.10(8), 2879–2890 (2004).
   PubMed Web of Science ®Google Scholar
• Fifis T, Mottram P, Bogdanoska V, Hanley J, Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine23(2), 258–266 (2004).
   PubMed Web of Science ®Google Scholar
• Schnurr M, Chen Q, Shin A et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood105(6), 2465–2472 (2005).
   PubMed Web of Science ®Google Scholar
• Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology109(3), 374–383 (2003).
   PubMed Web of Science ®Google Scholar
• Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology110(1), 95–104 (2003).
   PubMed Web of Science ®Google Scholar
• Boyle J, Eastman D, Millar C et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine25(14), 2541–2544 (2007).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science305, 205–208 (2004).
   PubMed Web of Science ®Google Scholar
• Sjölander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine19(17–19), 2661–2665 (2001).
   PubMed Web of Science ®Google Scholar
• Le TTT, Drane D, Malliaros J et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine19(32), 4669–4675 (2001).
   PubMed Web of Science ®Google Scholar
• Polakos NK, Drane D, Cox J et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol.166(5), 3589–3598 (2001).
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev.188, 22–32 (2002).
   PubMed Web of Science ®Google Scholar
• Pearse MJ, Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev.57(3), 465–474 (2005).
   PubMed Web of Science ®Google Scholar
• Kashala O, Amador R, Valero MV et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine20(17–18), 2263–2277 (2002).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine23(20), 2591–2601 (2005).
   PubMed Web of Science ®Google Scholar